[144] Humacyte, Inc. SEC Filing
Form 144 notice for HUMA (Humacyte, Inc.) reporting a proposed sale of common stock. The filer plans to sell 549,360 shares through UBS Financial Services Inc. on or about 08/18/2025, with an aggregate market value of $1,002,928.10. The company has 158,372,173 shares outstanding. The securities were originally acquired on 08/26/2021 as an early-stage investment in AHAC and converted to Humacyte shares when the company went public via SPAC; the original acquired amount shown is 18,930,004 shares with payment listed as cash. No securities were reported sold in the past three months. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Avviso Form 144 per HUMA (Humacyte, Inc.) relativo alla proposta vendita di azioni ordinarie. Il dichiarante prevede di vendere 549.360 azioni tramite UBS Financial Services Inc. in data approssimativa 08/18/2025, per un valore di mercato complessivo di $1,002,928.10. La società conta 158,372,173 azioni in circolazione. I titoli erano stati acquisiti originariamente il 08/26/2021 come investimento in fase iniziale in AHAC e sono stati convertiti in azioni Humacyte quando la società è diventata pubblica tramite SPAC; l'importo originario acquisito indicato è 18,930,004 azioni con pagamento in contanti. Non risultano titoli venduti negli ultimi tre mesi. L'avviso riporta la consueta dichiarazione secondo cui il venditore non è a conoscenza di informazioni materiali sconosciute e sfavorevoli.
Aviso Formulario 144 para HUMA (Humacyte, Inc.) que informa una propuesta de venta de acciones ordinarias. El declarante planea vender 549.360 acciones a través de UBS Financial Services Inc. aproximadamente el 08/18/2025, con un valor de mercado agregado de $1,002,928.10. La compañía tiene 158,372,173 acciones en circulación. Los valores fueron adquiridos originalmente el 08/26/2021 como una inversión en etapa temprana en AHAC y se convirtieron en acciones de Humacyte cuando la compañía salió a bolsa mediante una SPAC; la cantidad originalmente adquirida indicada es 18,930,004 acciones con pago en efectivo. No se reportaron ventas de valores en los últimos tres meses. El aviso incluye la representación estándar de que el vendedor no tiene conocimiento de información adversa material no divulgada.
HUMA(휴머싸이트, Humacyte, Inc.)에 대한 Form 144 통지 — 보통주 매도 예정 보고. 제출자는 08/18/2025경 UBS Financial Services Inc.를 통해 549,360주를 매도할 계획이며, 총 시가 가치는 $1,002,928.10입니다. 회사의 발행 주식 수는 158,372,173주입니다. 해당 증권은 원래 08/26/2021에 AHAC에 대한 초기 투자로 취득되었고, 회사가 SPAC을 통한 상장 시 Humacyte 주식으로 전환되었습니다; 원래 취득한 수량은 18,930,004주이며 결제 방식은 현금으로 기재되어 있습니다. 최근 3개월 동안 보고된 매도는 없습니다. 통지서에는 판매자가 공개되지 않은 중대한 불리한 정보를 알고 있지 않다는 일반적인 진술이 포함되어 있습니다.
Avis Formulaire 144 pour HUMA (Humacyte, Inc.) signalant une proposition de vente d'actions ordinaires. Le déclarant prévoit de vendre 549,360 actions via UBS Financial Services Inc. aux alentours du 08/18/2025, pour une valeur de marché globale de $1,002,928.10. La société possède 158,372,173 actions en circulation. Les titres ont été initialement acquis le 08/26/2021 dans le cadre d'un investissement en phase initiale dans AHAC et convertis en actions Humacyte lorsque la société est entrée en bourse via une SPAC ; le montant initial acquis indiqué est de 18,930,004 actions avec paiement en espèces. Aucun titre n'a été déclaré vendu au cours des trois derniers mois. L'avis inclut la déclaration habituelle selon laquelle le vendeur n'a pas connaissance d'informations défavorables importantes non divulguées.
Form 144-Mitteilung für HUMA (Humacyte, Inc.) zur geplanten Veräußerung von Stammaktien. Der Einreichende beabsichtigt, am oder um den 08/18/2025 über UBS Financial Services Inc. 549.360 Aktien zu verkaufen, mit einem Gesamtmarktwert von $1,002,928.10. Das Unternehmen hat 158,372,173 ausstehende Aktien. Die Wertpapiere wurden ursprünglich am 08/26/2021 als Frühphaseninvestition in AHAC erworben und bei dem Börsengang über eine SPAC in Humacyte-Aktien umgewandelt; der ursprünglich erworbene Betrag wird mit 18,930,004 Aktien angegeben, die Zahlung erfolgte in Bargeld. In den letzten drei Monaten wurden keine Verkäufe gemeldet. Die Mitteilung enthält die übliche Zusicherung, dass der Verkäufer keine Kenntnis von nicht offengelegten wesentlichen nachteiligen Informationen hat.
- None.
- None.
Insights
TL;DR: Routine Rule 144 sale notice: modest block listed for sale relative to total shares outstanding; appears procedural, not a disclosed material event.
The filing is a standard Form 144 reporting a proposed sale of 549,360 common shares via UBS with an aggregate market value of $1.00M. Compared with the issuer's reported 158.37M shares outstanding, the block represents roughly 0.35% of outstanding shares, suggesting limited supply-side impact. The acquisition history shows these shares originated from a pre-public investment converted at SPAC closing on 08/26/2021. No sales in the past three months are reported. From a securities-flow perspective, this notice is informational and does not, by itself, signal a material corporate development.
TL;DR: Filing is procedural and includes the seller's standard attestation about undisclosed material information.
The Form 144 includes the usual signature/attestation language confirming the filer does not possess undisclosed material adverse information and notes the acquisition origin (early-stage investor in AHAC converted at IPO). The filing does not disclose any insider trading plan or 10b5-1 adoption date. Because the document contains no executive departures, related-party transactions beyond the conversion note, or governance actions, it appears to be a routine liquidity notice rather than a governance event.
Avviso Form 144 per HUMA (Humacyte, Inc.) relativo alla proposta vendita di azioni ordinarie. Il dichiarante prevede di vendere 549.360 azioni tramite UBS Financial Services Inc. in data approssimativa 08/18/2025, per un valore di mercato complessivo di $1,002,928.10. La società conta 158,372,173 azioni in circolazione. I titoli erano stati acquisiti originariamente il 08/26/2021 come investimento in fase iniziale in AHAC e sono stati convertiti in azioni Humacyte quando la società è diventata pubblica tramite SPAC; l'importo originario acquisito indicato è 18,930,004 azioni con pagamento in contanti. Non risultano titoli venduti negli ultimi tre mesi. L'avviso riporta la consueta dichiarazione secondo cui il venditore non è a conoscenza di informazioni materiali sconosciute e sfavorevoli.
Aviso Formulario 144 para HUMA (Humacyte, Inc.) que informa una propuesta de venta de acciones ordinarias. El declarante planea vender 549.360 acciones a través de UBS Financial Services Inc. aproximadamente el 08/18/2025, con un valor de mercado agregado de $1,002,928.10. La compañía tiene 158,372,173 acciones en circulación. Los valores fueron adquiridos originalmente el 08/26/2021 como una inversión en etapa temprana en AHAC y se convirtieron en acciones de Humacyte cuando la compañía salió a bolsa mediante una SPAC; la cantidad originalmente adquirida indicada es 18,930,004 acciones con pago en efectivo. No se reportaron ventas de valores en los últimos tres meses. El aviso incluye la representación estándar de que el vendedor no tiene conocimiento de información adversa material no divulgada.
HUMA(휴머싸이트, Humacyte, Inc.)에 대한 Form 144 통지 — 보통주 매도 예정 보고. 제출자는 08/18/2025경 UBS Financial Services Inc.를 통해 549,360주를 매도할 계획이며, 총 시가 가치는 $1,002,928.10입니다. 회사의 발행 주식 수는 158,372,173주입니다. 해당 증권은 원래 08/26/2021에 AHAC에 대한 초기 투자로 취득되었고, 회사가 SPAC을 통한 상장 시 Humacyte 주식으로 전환되었습니다; 원래 취득한 수량은 18,930,004주이며 결제 방식은 현금으로 기재되어 있습니다. 최근 3개월 동안 보고된 매도는 없습니다. 통지서에는 판매자가 공개되지 않은 중대한 불리한 정보를 알고 있지 않다는 일반적인 진술이 포함되어 있습니다.
Avis Formulaire 144 pour HUMA (Humacyte, Inc.) signalant une proposition de vente d'actions ordinaires. Le déclarant prévoit de vendre 549,360 actions via UBS Financial Services Inc. aux alentours du 08/18/2025, pour une valeur de marché globale de $1,002,928.10. La société possède 158,372,173 actions en circulation. Les titres ont été initialement acquis le 08/26/2021 dans le cadre d'un investissement en phase initiale dans AHAC et convertis en actions Humacyte lorsque la société est entrée en bourse via une SPAC ; le montant initial acquis indiqué est de 18,930,004 actions avec paiement en espèces. Aucun titre n'a été déclaré vendu au cours des trois derniers mois. L'avis inclut la déclaration habituelle selon laquelle le vendeur n'a pas connaissance d'informations défavorables importantes non divulguées.
Form 144-Mitteilung für HUMA (Humacyte, Inc.) zur geplanten Veräußerung von Stammaktien. Der Einreichende beabsichtigt, am oder um den 08/18/2025 über UBS Financial Services Inc. 549.360 Aktien zu verkaufen, mit einem Gesamtmarktwert von $1,002,928.10. Das Unternehmen hat 158,372,173 ausstehende Aktien. Die Wertpapiere wurden ursprünglich am 08/26/2021 als Frühphaseninvestition in AHAC erworben und bei dem Börsengang über eine SPAC in Humacyte-Aktien umgewandelt; der ursprünglich erworbene Betrag wird mit 18,930,004 Aktien angegeben, die Zahlung erfolgte in Bargeld. In den letzten drei Monaten wurden keine Verkäufe gemeldet. Die Mitteilung enthält die übliche Zusicherung, dass der Verkäufer keine Kenntnis von nicht offengelegten wesentlichen nachteiligen Informationen hat.
FAQ
What shares does Humacyte (HUMA) plan to sell according to this Form 144?
What is the reported aggregate market value of the proposed HUMA sale?
When were the shares being sold originally acquired?
How many Humacyte shares are outstanding per this filing?
Does the Form 144 report any securities sold by the filer in the past three months?
